ORLANDO—Computed tomography (CT) scanning and blood tests to determine tumor markers are very important in the follow-up of stage I nonseminomatous testicular cancer (NSTC), but the physical examination is of limited value, according to new research presented in a poster session.
SAN DIEGO—Prostate cancer patients who are treated with a combination of androgen deprivation therapy (ADT) and radiotherapy may have a substantially improved chance of survival compared with patients who do not receive radiotherapy, according to British researchers. They reported at the 52nd annual meeting of the American Society for Radiation Oncology that combination therapy resulted in substantial benefits in overall survival and disease-specific survival in men with locally advanced prostate cancer.
SAN FRANCISCO—Two new studies presented at the 2010 annual meeting of the American Urological Association (AUA) suggest that large-scale prostate cancer screenings can indeed save lives.
Researchers in Innsbruck, Austria, evaluated data from the state of Tyrol within Austria, where an early detection and treatment program has been in place for more than 20 years. They found that these programs have been associated with a reduction in mortality in areas where effective treatment is available to all men.
CHICAGO—Cabazitaxel is the first treatment to show a survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC), according to data from a phase 3 trial.
On June 17, cabazitaxel became the first drug approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer. Results from the phase 3 trial delivered at ASCO were included in the FDA review.
Chemotherapy appears to be associated with a statistically significant decrease in the relative risk of prostate cancer-specific mortality among older men with stage IV prostate cancer who are receiving androgen-deprivation therapy (ADT), according to a new study.
Most cases of severe treatment-related adverse reactions to the targeted therapies for kidney cancer appear to be reversible and resolve after dose reduction or treatment in terruption, according to Thomas Hutson, DO, PharmD, director of genitourinary oncology at Baylor Sammons Cancer Center, Dallas, Texas.
Approximately 192,000 men developed prostate cancer in 2009 and 27,000 died from the disease.1 Prostate cancer is the most frequently diagnosed cancer in North America and the second most common cause of cancer death in men. Although the number of new cases of prostate cancer has increased in the past decade, the absolute number of deaths has slowly declined.1 As the incidence of prostate cancer increases, controversies continue about the best possible methods for screening, detection, and treatment.
The past 5 years have ushered in a new era in the treatment of kidney cancer, and new medications are giving patients more options than ever before. In addition, the traditional end points in oncology drug development, such as survival and tumor response, are changing when it comes to this tumor type. The goal of therapy now is to improve symptomatic and functional ability in patients with renal cell carcinoma (RCC).
Results 81 - 88 of 88